Search research articles
Contact Us
Filters
Showing results (131-140 of 536) with videos related to
Page
of 54
Sort By:
The Journal of Pharmacology and Experimental Therapeutics
|
January 7, 2005
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1
Jim J Xiao, Amy B Foraker, Peter W Swaan, et al.
Cancer
|
May 31, 2007
Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality
Naeem A Ali, James M O'Brien, William Blum, et al.
British Journal of Haematology
|
June 10, 2025
The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission
Jose Tinajero, Dat Ngo, Maria Motta, et al.
Leukemia & Lymphoma
|
August 20, 2013
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia
Alison R Walker, Rebecca B Klisovic, Ramiro Garzon, et al.
Blood Cancer Journal
|
October 4, 2022
TET2 deficiency promotes MDS-associated leukemogenesis
Feiteng Huang, Jie Sun, Wei Chen, et al.
Blood
|
July 23, 2016
CBFβ-SMMHC creates aberrant megakaryocyte-erythroid progenitors prone to leukemia initiation in mice
Qi Cai, Robin Jeannet, Wei-Kai Hua, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 13, 2006
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation
Navin Wadehra, Sherif Farag, Brian Bolwell, et al.
Blood Cancer Journal
|
November 28, 2023
Correction: TET2 deficiency promotes MDS-associated leukemogenesis
Feiteng Huang, Jie Sun, Wei Chen, et al.
Leukemia & Lymphoma
|
April 4, 2013
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101
Jeffrey A Jones, Amy S Ruppert, Weiqiang Zhao, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2008
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804
Richard M Stone, Kathleen A Donohue, Wendy Stock, et al.
Page
of 54
Search research articles
Search
Showing results (131-140 of 536) with videos related to
Sort By:
Page
of 54
The Journal of Pharmacology and Experimental Therapeutics
|
January 7, 2005
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1
Jim J Xiao, Amy B Foraker, Peter W Swaan, et al.
Cancer
|
May 31, 2007
Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality
Naeem A Ali, James M O'Brien, William Blum, et al.
British Journal of Haematology
|
June 10, 2025
The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission
Jose Tinajero, Dat Ngo, Maria Motta, et al.
Leukemia & Lymphoma
|
August 20, 2013
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia
Alison R Walker, Rebecca B Klisovic, Ramiro Garzon, et al.
Blood Cancer Journal
|
October 4, 2022
TET2 deficiency promotes MDS-associated leukemogenesis
Feiteng Huang, Jie Sun, Wei Chen, et al.
Blood
|
July 23, 2016
CBFβ-SMMHC creates aberrant megakaryocyte-erythroid progenitors prone to leukemia initiation in mice
Qi Cai, Robin Jeannet, Wei-Kai Hua, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 13, 2006
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation
Navin Wadehra, Sherif Farag, Brian Bolwell, et al.
Blood Cancer Journal
|
November 28, 2023
Correction: TET2 deficiency promotes MDS-associated leukemogenesis
Feiteng Huang, Jie Sun, Wei Chen, et al.
Leukemia & Lymphoma
|
April 4, 2013
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101
Jeffrey A Jones, Amy S Ruppert, Weiqiang Zhao, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2008
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804
Richard M Stone, Kathleen A Donohue, Wendy Stock, et al.
Page
of 54